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The incidence of lung cancer has been increasing while death rates
from cancer have declined in most developed countries during the
past 20 years. In the USA it is the leading cause of death as a result
of a more than threefold increase during the same time period.
Although there has been a recent decline in the USA and Canada,
the death rate from lung cancer in developing countries continues
to accelerate (de Vita et al, 1997).
Because relapse is frequent after resection of even early-stage
non-small-cell lung cancer (NSCLC), the long-term survival rate
remains disappointingly poor (de Vita et al, 1997). The two major
prognostic factors for patients with early-stage resectable cancers
are the size of the tumour and the presence or absence of lymph
node metastasis (Mountain, 1986; Naruke et al, 1988).
Histological subtype may provide some additional prognostic
information; outcomes of large-cell lung cancers are the least
favourable subtype while resected squamous cell carcinomas and
adenocarcinomas have a more favourable prognosis (Kayser et al,
1987; Mountain et al, 1987). Other poor prognostic factors include
lack of tumour differentiation, lymphatic vessel invasion in
patients with metastasis-free lymph nodes, blood vessel invasion,
high mitotic index, loss or alteration of the expression of blood
group antigens on the tumour cells, the presence of tumour-associ-
ated carbohydrate antigens, aneuploid y, high S phase fraction on
flow cytometry, increased proliferating cell nuclear antigen
(PCNA) index, elevated level of serine proteases like urokinase
and plasminogen, and a high microvessel count (Rosvold, 1996).
With the advance in molecular biology some genetic changes
have been suggested to be useful prognostic markers. Mutations in
K-ra s (Mitsudomi et al, 1991), overexpression of c-erbB-2 protein
(Kern et al, 1990, 1994; Tateishi et al, 1991), mutation of p53
(Mitsudomi et al, 1993) and lack of Rb1 (Xu et al, 1994) or bcl-2
protein expression (Pezzella et al, 1993; Fontanini et al, 1995)
have all been reported as adverse prognostic factors.
Recently, in addition to mitogens and tumour suppressor genes,
some of the essential components of cell cycle machinery itself
have been found to show oncogenic potential (Motokura and
Arnold, 1993; Lovec et al, 1994). Among them, cyclin D1 appears
to be the most strongly implicated in tumorigenesis. Cyclin D1 has
a regulatory role in the G1 to S transition of the cell division cycle.
There have been genetic evidences of tumour-specific rearrange-
ments and amplifications of the cyclin D1 gene in the experi-
mental-induced malignant phenotype (Bartkova et al, 1994; Lovec
et al, 1994; Lukas et al, 1994; Wang et al, 1994).
The role of cyclin D1 protein in human cancers has recently
been able to be performed in a large scale using a monoclonal anti-
body specific for this oncoprotein with an optimizing protocol for
immunohistochemical detection of cyclin D1 on archival tissue
sections (Gillett et al, 1994; Bartkova et al, 1995). Some of the
human primary cancers have been found to have amplification or
overexpression of the relevant gene locus of cyclin D1 including
breast (Gillett et al, 1994; McIntosh et al, 1995; Simpson et al,
1997), oesophagus (Jiang et al, 1992; Adelaide et al, 1995), liver
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Summar yCyclin D1 is one of the G1 cyclins that control cell cycle progression by allowing G1 to S transition. Overexpression of cyclin D1
has been postulated to play an important role in the development of human cancers. We have investigated the correlation between cyclin D1
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patients. Formalin-fixed and paraffin-embedded tumour tissues resected from 69 NSCLC patients between stages I and IIIa were
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cyclin D1. Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with
advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). Twenty-four patients with cyclin D1-
positive immunoreactivity revealed a significantly shorter overall survival than the patients with negativity (24.0 ± 3.9 months vs 50.1 ± 6.4
months, P = 0.0299). Among 33 patients between stages I and II, nine patients with cyclin D1-positive immunoreactivity had a much shorter
overall survival (29.7 ± 6.1 months vs 74.6 ± 8.6 months, P = 0.0066). These results suggest that cyclin D1 overexpression is involved in
tumorigenesis of NSCLCs from early stage and could be a predictive molecular marker for poor prognosis in resectable NSCLC patients,
which may help us to choose proper therapeutic modalities after resection of the tumor.
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A few studies have reported that overexpression of cyclin D1 is
implicated in the tumorigenesis of NSCLCs (Betticher et al, 1996;
Kwa et al, 1996; Mate et al, 1996; Caputi et al, 1997). However,
there has been controvery and limited available data for the
significance of cyclin D1 overexpression on the prognosis of
NSCLC patients. In the present study, we have investigated
whether immunohistochemically detected cyclin D1 overexpres-
sion is associated with the survival of patients with early-stage
resectable NSCLCs.
MATERIALS AND METHODS
Tumour samples
The tumour specimens were obtained from lobectomies or pneu-
monectomies performed at the Hanyang University Hospital
placed in Seoul, Korea between 1985 and 1994. Consecutive 69
NSCLC patients with resectability were selected after pathological
examination of the formalin-fixed and paraffin-embedded tumour
specimens (stage I—IIIa) (stage I (T1—2 N0 M0), stage II (T1—2 N1
M0), stage IIIa (T1—3 N2 M0, T3 N0 M0, T3 N1 M0)) (Mountain,
1986). The patients had been followed up through a period ranging
from 0.5 to 108 months after resection of the primary tumour.
Immunohistochemical study
Immunohistochemical staining was performed by the method
previously described (Shin et al, 1997). Briefly, representative
tissue sections from 69 cases were deparaffinized and rehydrated.
After boiling the slides in a microwave oven (containing 0.01 M
sodium citrate buffer pH 6.0; 800 W), endogenous peroxidase was
blocked with 3% hydrogen peroxide—methanol. After washing
with cold 0.5 M Tris-buffered saline (TBS), non-specific binding
was inhibited by incubation with normal goat serum (Dako,
Carpenteria, CA, USA) for 20 min. Monoclonal mouse antihuman
cyclin D1 (P2D11F11, 1:200 in dilution, Novocastra, Newcastle,
UK) and PCNA antibodies (PC10, 1:100 in dilution; Dako) were
applied and incubated for 30 min. After washing with TBS three
times, the sections were incubated with biotinylated antimouse
IgG (Dako) for 30 min. After washing, peroxidase—antiperoxidase
conjugate (Dako) was applied. They were then stained with
diaminobenzidine tetrahydrochloride (Dako) and counterstained
with Meyer￿s haematoxylin. Positive control was identified on the
sections from formalin-fixed and paraffin-embedded WI-38 cells
(ATCC, Rockville, MD, USA) for cyclin D1. Negative control was
accompanied by applying phosphate-buffered saline instead of
cyclin D1 and PCNA antibodies.
Analysis
Immunohistochemical reactivity of cyclin D1 was interpreted as
positive when there was distinct nuclear staining with a brownish
tincture in more than 5% of the tumour cell population
(Michalides et al, 1995; Shin et al, 1997) (Figure 1A). For PCNA,
distinct nuclear staining with a brownish tincture was considered
as positive and the index of PCNA was calculated in percentage of
positive cells among approximately 1000 counted tumour cells
(Figure 1B).
The correlation of cyclin D1 immunoreactivity with clinical
factors such as age, sex, histopathological type, stage of the
tumour, extent of the primary tumour, metastatic status of the
lymph node and PCNA index was analysed through the
Mann—Whitney U-test or analysis of variance (ANOVA)
according to the characteristics of the data. Overall survival in
relation to cyclin D1 immunoreactivity was analysed with the
Kaplan—Meier method, and their difference with the log-rank test.
Multivariate analysis for survival was assessed using a forward
step-wise Cox regression model. The variables included tumour
(T) and nodal status of TMN system, stage of the tumour and
cyclin D1 positivity. The statistical analysis was performed using
the SPSS 7.5 software package (SPSS Inc., Chicago, IL, USA).
P < 0.05 was considered statistically significant.
RESULTS
Clinical features
Among 69 patients, 53 were men and 16 were women. The age
difference ranged from 40 to 73 years (mean 57.2 years). The
clinical follow-up period was between 0.5 months and 108
months. Twenty cases were in stage I, 13 in stage II and 36 in stage
IIIa. There were 41 squamous cell carcinomas, 21 adenocarci-
nomas and seven large-cell undifferentiated carcinomas. Two
giant cell carcinomas were included in the latter group. Five were
T1, 43 T2 and 21 T3 in accordance with the extent of the primary
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Figure 1 Immunohistochemical stainings of poorly differentiated squamous
cell carcinoma for cyclin D1 (A) and PCNA (B) show distinct intranuclear
immunoreactivitytumour. Twenty-seven patients were free of tumour metastasis in
both dissected and biopsied lymph nodes. Twenty-one patients
showed ipsilateral bronchopulmonary or hilar nodal metastasis
and the other 21 patients had metastasis in the ipsilateral
subcarinal mediastinal lymph node.
Immunohistochemical analysis of cyclin D1
Twenty-four tumours (34.8%) revealed positive immunoreactivity
for cyclin D1. The relationship between cyclin D1 immunoreac-
tivity and clinicopathological features are summarized in Table 1.
Cyclin D1 overexpression was higher in female patients (50%)
than in male patients (30.9%), but there was no significant
difference between the two groups (P = 0.394). The cyclin D1
immunopositive group was slightly younger than the negative
group with no significant difference (P = 0.347). Among the three
histopathological subgroups, adenocarcinoma showed the most
frequent positivity (47.6%) followed by squamous cell carcinoma
and large-cell carcinoma (31.7% and 14.3% respectively).
However, no significant difference was present among the three
groups (P = 0.784). Although all five T1 tumours showed no
immunoreactivity, T2 and T3 tumours revealed 39.5 and 33.3% of
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Table 1 Cyclin D1 immunoreactivity and clinicopathological features
Cyclin D1 – Cyclin D1 + Positive (%) P-valuea
Number of patients 69 (total) 45 24 34.8
Sex Male 38 17
0.394
Female 7 7
Age 57.2 ± 8.4 (total) 57.9 ± 7.4 55.7 ± 10.1 0.347b
Subtype Squamous 28 13 31.7
Adeno 11 10 47.6 0.784
Large cell 6 1 14.3
Primary tumour tumour T1 5 0 0
T2 26 17 39.5 0.637
T3 14 7 33.3
Lymph node N0 24 3 11.1
metastasis N1 11 10 47.6 0.002
N2 10 11 52.4
Stage I 18 2 10.0
II 6 7 53.8 0.048
IIIa 21 15 41.7
aMann–Whitney U-test; bt-test.
Table 2 Survival functions (Kaplan–Meier) of the 69 patients according to various factors
Number of Survival timea Per cent
Factor patients (Mean ± S.D.) censored P-valueb
Sex Female 16 47.4 ± 10.4 31.25 0.6129
Male 53 41.8 ± 5.7 30.19
Tumour type
Squamous 41 48.3 ± 6.4 41.5
Adeno 21 36.2 ± 8.2 19.1 0.1887
Large cell 7 27.4 ± 5.5 0
T status  T1 5 66.9 ± 19.8 60.0
T2 43 47.6 ± 6.5 34.9 0.0133
T3 21 24.5 ± 5.6 14.3
N status N0 27 66.1 ± 8.1 51.9
N1 21 35.8 ± 8.4 28.6 0.0002
N2 21 20.8 ± 3.7 4.8
Stage I 20 79.18.5 65.0
II 13 35.78.9 30.8 < 0.00001
III 36 22.93.7 11.1
Cyclin D1 – 45 50.1 ± 6.4 35.6 0.0299
+ 24 24.0 ± 3.9 20.8
Cyclin D1c – 24 74.6 ± 8.6 62.5 0.0066
+ 9 29.7 ± 6.1 22.2
S.D., standard deviation; amonths; blog-rank test; conly stage I and II.positive immunoreactivity respectively. There was no significant
difference (P = 0.637).
Cyclin D1 immunoreactivity was well correlated with lymph
node metastasis and the stage of the tumour. Twenty-one of 42
NSCLCs with lymph node metastasis (50%) showed positive
immunoreactivity for cyclin D1. However, only three of 27 nodal
metastasis-free cases (11%) disclosed cyclin D1-positive
immunoreactivity. This difference was highly significant
(P = 0.002). According to the stage of the tumour, stage I showed
a lower cyclin D1-positive immunoreactivity than stages II and
IIIa (10%, 53.8%, and 41.7% respectively). There were significant
differences (P = 0.006 for stage I vs II, IIIa; P = 0.048 for the three
groups).
PCNA index
All tumours showed a variable degree of positive immunoreac-
tivity for the PCNA protein in their nuclei. However, there was no
significant difference in different groups according to sex,
histopathological subtype, extent of the primary tumour (T status),
nodal status, or stage of the tumour (ANOVA). The PCNA index
was slightly higher in cyclin D1-positive groups in comparison
with cyclin D1-negative groups (53.2% vs 47.3% respectively).
However, no significant difference was present (ANOVA,
P = 0.117).
Survival of the patients
The overall survival ranged from 0.5 to 108 months. During the
follow-up period a total of 48 patients (30.4%) died and 21 were
censored. The survival of the total 69 patients according to various
factors are presented in Table 2. The overall survival in the present
study was significantly correlated with the extent of the primary
tumour, nodal status and stage of the tumour (log-rank;
P = 0.0133, P = 0.0002 and P < 0.00001 respectively). However,
the histological type of the NSCLC and sex of the patients were
not correlated with patient survival (P = 0.1887 and 0.6129 respec-
tively). Sixteen of 45 cyclin D1-negative cases (35.6%) were
censored. The mean survival of the cyclin D1-negative groups was
significantly longer than that of the cyclin D1-positive groups
(50.1 ± 6.4 months vs 24.0 ± 3.9 months, P = 0.029). An analysis
of the overall survival in stages I—II and stages I—IIIa revealed that
cyclin D1-positive immunoreactivity was strongly associated with
a poorer overall survival (P = 0.0066 and P = 0.0299 respectively;
Figure 2). Multivariate analysis showed that the stage of the
tumour was the strongest prognostic factor (P = 0.0082). How-
ever, cyclin D1-positive immunoreactivity was not significant
(P = 0.3878) (Table 3).
DISCUSSION
Abnormal expression of cell cycle-regulatory proteins commonly
occur in various human cancers (Motokura et al, 1993; Bartkova
et al, 1994; Lovec et al, 1994; Lukas et al, 1994; Wang et al, 1994).
One of the most frequent derangements is altered expression of
cyclin D1. Cyclin D1 is encoded by CCND1 (PRAD1 and BCL-1)
located in the chromosome 11q13 region which also harbours
EMSI, HSTF1 and INT2 genes. Cyclin D1 protein stimulates
cyclin-dependent kinase (cdk)-mediated phosphorylation of the
retinoblastoma susceptibility gene (Rb) product, which inactivates
its growth-suppressive role to the transcription factor E2F. The
cyclin—cdk complexes lead to transition of cell division from G1 to
S phase, thus contributing to tumorigenesis in many organs by
continuing cell cycle progression when they are overexpressed
(Kastan and Tooze, 1997).
In the present study, we detected cyclin D1 overexpression in
resected specimens of NSCLC patients using immunohisto-
chemical methods. Twenty-four among 69 patients (34.8%)
showed positive immunoreactivity for cyclin D1, which was in the
range of previous studies reporting from 18% to 57.1% (Betticher
et al, 1996; Kwa et al, 1996; Mate et al, 1996; Caputi et al, 1997).
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Figure 2 Kaplan–Meier’s survival curves according to immunureactivity for
cyclin D1 with stages I–IIIa (A) and stages I–II (B) (log-rank; P = 0.0299 for
stage I–IIIa, P = 0.0066 for stage I–II)
Table 3 Multivariate Cox’s analysis for independent predictors of survivals
b (S.E.) P-value
Stage 0.829 (0.314) 0.0082
Tumur status 0.072 (0.344) 0.8352
Nodal status 0.145 (0.443) 0.7436
Cyclin D1 0.277 (0.320) 0.3878
b is the coefficient of the regression model. S.E., standard error.There have been several reports which showed the correlation
of cyclin D1 overexpression or amplification of cyclin D1 gene
(CCND1) with pathological prognostic factors and patient
outcome in various human cancers. Cyclin D1 gene expression
or amplification was associated with not only lymph node metas-
tasis but also with shorter relapse-free survival in breast, head
and neck, and urinary bladder cancers (Proctor et al, 1991;
Schuuring et al, 1992; Jares et al, 1994; Muller et al, 1994;
McIntosh et al, 1995; ￿kervall et al, 1997; Shin et al, 1997).
With respect to lung cancer, however, there were a few studies
reported in the English literature (Betticher et al, 1996; Kwa
et al, 1996; Mate et al, 1996; Caputi et al, 1997). There has been
controversy, especially considering the significance of cyclin D1
overexpression on the prognosis of NSCLC patients. Betticher
et al (1996) reported that cyclin D1 overexpression has been
associated with some pathological parameters such as poorly
differentiated histology, less infiltration of lymphocyte and a low
incidence of local relapse, which suggested cyclin D1 over-
expression as a good prognostic factor. On the other hand, Caputi
et al (1997) demonstrated that overexpression of cyclin D1 was
significantly related to short-term patient survival. In the present
study, cyclin D1 overexpression in resectable NSCLCs was
significantly associated with a shorter overall survival, which is
compatible with the results of Caputi et al (1997). Moreover, our
data revealed that overexpression of cyclin D1 was also corre-
lated with lymph node metastasis and pathological staging.
Therefore, it is suggested that cyclin D1 overexpression detected
by immunohistochemical staining may be an indicator of poor
prognosis in primary NSCLCs with resectability.
Furthermore, our results revealed that cyclin D1 overexpression
was much more strongly correlated with the overall survival
among the patients with stages I and II (P = 0.0066 for stages I and
II vs P = 0.0299 for stages I—IIIa). Nine among 33 patients with
stages I and II NSCLCs revealed positive immunoreactivity
(27.3%), but 15 among 36 (41.7%) stage IIIa patients showed posi-
tivity. These findings suggest that overexpression of cyclin D1 can
be involved in the tumorigenesis from earlier stages and may play
a role in tumour progression to higher stages, which is similar to
those of superficial urinary bladder cancers (Shin et al, 1997).
Our data revealed that there was no significant correlation of
cyclin D1 overexpression with histological subtypes of NSCLC.
This result may come from the fact that cyclin D1 overexpression
is a rather conserved mechanism which is commonly involved in
the tumorigenesis of various cell types of NSCLCs.
Mediastinal lymph node involvement in NSCLC is a crucial
prognostic factor. Strong correlation between micrometastasis or
minimal residual disease of mediastinal lymph nodes detected by
immunohistochemical staining and the relapse-free survival or
overall survival in stage I NSCLCs further supports the importance
of lymph node involvement in the progression of NSCLCs (Izbicki
et al, 1996). In this study, our data demonstrated a strong correla-
tion of cyclin D1 overexpression with lymph node metastasis.
This result suggests that metastatic potential in NSCLCs with
resectability may become expressed through a way related to
deregulation of cyclin D1. Mathematical studies suggest that cells
probably need to accumulate at least four to six mutations to
become tumorigenic. And each mutation should be required for an
expansion of the mutant clone to at least a million cells (20
doublings) in which the next mutation can occur (Shay et al,
1993). These cell doublings can be achieved through the extended
activity of cyclin D1 protein. Overexpression of cyclin D1 should
account for their extended activity and clonal expansion of cells
that have progression activity such as metastatic potential, thus
implicating on the survival of the patients. Taken together with this
theoretical background and our results for cyclin D1 protein,
correlation of cyclin D1 overexpression with lymph node metas-
tasis may strongly support a possible contribution of cyclin D1
overexpression to the progression and prognosis of NSCLCs.
Overexpression of cyclin D1 is believed to be correlated with
increased proliferative activity, as seen in head and neck squamous
cell carcinomas measured by flow cytometry (Callender et al,
1994). But it was difficult to validate correlation with other
methods using bromodeoxyuridine labelling or Ki-67 (MIB-1)
labelling indices (Zukerberg et al, 1995b). In the present study, we
also measured the proliferative activity by the PCNA index using
immunohistochemistry and obtained higher proliferative activity
in cyclin D1-positive immunoreactive tumors than in cyclin
D1-negative ones. However, no statistically significant difference
was present between the two groups.
Cyclin D1 overexpression does not always mean a sine qua non
amplification of CCND1. It has been suggested that mechanisms
other than gene amplification may play a role in carcinogenesis of
lung cancer including increased stability of the protein of clonal
rearrangement of CCND1 gene (Zukerberg et al, 1995a).
According to the cytogenetic study, chromosome 11q13 rearrange-
ments were weakly correlated with immunohistochemical over-
expression of cyclin D1, although it was a significant prognostic
indicator of a poor outcome in head and neck cancers (￿kervall
et al, 1997). In NSCLC it also remains to be elucidated whether
some putative oncogenes or tumour suppressor genes within the
amplicon 11q13 region other than CCND1 may be involved in the
tumorigenesis.
In conclusion, our results of cyclin D1 overexpression in
relation to various clinicopathological parameters suggest that
overexpression of cyclin D1 is involved in tumorigenesis of
NSCLC from early stage and could be a molecular marker for a
poorer outcome and progression in NSCLCs with resectability.
Therefore, cyclin D1 overexpression, especially in patients with
stages I and II NSCLCs, may help us to determine its biological
behaviour and to choose proper therapeutic modalities following
tumour resection.
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